ReviewClinical cancer research : an official journal of the American Association for Cancer Research2008
Advances in targeting IKK and IKK-related kinases for cancer therapy.
Review in Clinical cancer research : an official journal of the American Association for Cancer Research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 109 citations in OpenAlex.
- FAM72A is associated with lung cancer proliferation and migration via the NF‑κB signaling pathway.Molecular genetics and genomics : MGG · 2026Article
- Tight junction-high and CDH17-positive cell population is the source of colorectal cancer liver metastases.Nature communications · 2026Article
- Yiqi Wenyang decoction protects against the development of atherosclerosis by inhibiting vascular inflammation.Pharmaceutical biology · 2025Article
- Investigating prognostic features in high-grade serous ovarian cancer through gene regulatory network inference with single-cell transcriptomic profiles.Scientific reports · 2025Article
- Interplay of Cellular Nrf2/NF-κB Signalling after Plasma Stimulation of Malignant vs. Non-Malignant Dermal Cells.International journal of molecular sciences · 2024Article
- Involvement of the AKT Pathway in Resistance to Erlotinib and Cabozantinib in Triple-Negative Breast Cancer Cell Lines.Biomedicines · 2023Article
- IκB kinase β (IKKβ): Structure, transduction mechanism, biological function, and discovery of its inhibitors.International journal of biological sciences · 2023Review
- Repurposing of known drugs for COVID-19 using molecular docking and simulation analysis.Bioinformation · 2023Article
- Identification of 1Journal of enzyme inhibition and medicinal chemistry · 2022Article
- IKKActa pharmaceutica Sinica. B · 2022Article
- The Synergy of ADAM17-Induced Myocardial Inflammation and Metabolic Lipids Dysregulation During Acute Stress: New Pathophysiologic Insights Into Takotsubo Cardiomyopathy.Frontiers in cardiovascular medicine · 2021Review
- Targeting AGTR1/NF-κB/CXCR4 axis by miR-155 attenuates oncogenesis in glioblastoma.Neoplasia (New York, N.Y.) · 2020Article
- Targeting IKKα kinase to prevent tumor progression and therapy resistance.Cancer drug resistance (Alhambra, Calif.) · 2020Review
- Targeting IκappaB kinases for cancer therapy.Seminars in cancer biology · 2019Review
- Xanthatin inhibits STAT3 and NF-κB signalling by covalently binding to JAK and IKK kinases.Journal of cellular and molecular medicine · 2019Article
- The natural flavonoid glycoside vitexin displays preclinical antitumor activity by suppressing NF-κB signaling in nasopharyngeal carcinoma.OncoTargets and therapy · 2019Article
- Oroxylin A Suppresses the Cell Proliferation, Migration, and EMT via NF-BioMed research international · 2019Article
- Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia.Blood advances · 2018Article
- Secondary Unconjugated Bile Acids Induce Hepatic Stellate Cell Activation.International journal of molecular sciences · 2018Article
- Epoxymicheliolide, a novelguaiane-type sesquiterpene lactone, inhibits NF‑κB/COX‑2 signaling pathways by targeting leucine 281 and leucine 25 in IKKβ in renal cell carcinoma.International journal of oncology · 2018Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
IkappaB kinases (IKK) and IKK-related kinases play critical roles in regulating the immune response through nuclear factor-kappaB and IFN regulatory factor-dependent signaling transduction cascades. Recently, these kinases have been implicated in the pathogenesis of many human diseases, including cancer. In fact, dysregulation of IKK activities promotes tumor survival, proliferation, migration, metastasis, and angiogenesis-common characteristics of many types of human cancers. Because of their oncogenic effects in human cancer development, targeting IKK and IKK-related kinases is becoming an increasingly popular avenue for the development of novel therapeutic interventions for cancer. This review will briefly cover the recent discovery of the downstream substrates of IKK and IKK-related kinases, and outline the strategies used for targeting IKK as a therapeutic intervention for cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.